The risk of acquiring genital papillomavirus infection (GPVI) is covariant with early sexual
debut, frequent partner changes, concurrent and previous other sexually transmitted …

Human papillomaviruses are among the most common sexually transmitted diseases in the
United States. Genital warts are a common phenotypic expression of human …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

This article critically reviews both established and experimental treatment modalities for
anogenital (AG) warts. Efficacy, cost, safety, advantages and disadvantages of each therapy …

Background Intralesional immunotherapy has been reported to be effective for warts and to
show good safety profiles, but this has not yet been systematically studied. Aims To …

An initial audit of the treatment of patients presenting to the GUM Department at Leeds
General Infirmary with a first episode of anogenital warts was reported in 1993. Treatment …

Introduction No hierarchy of first-line treatments for anogenital warts (AGWs) is provided in
international guidelines. This study aimed to determine the efficacy of topical treatments and …

External genital warts, caused by human papillomavirus, have a significant clinical,
epidemiological, and financial impact, including the risk for malignant transformation …

Background Anogenital warts (AGW) can cause economic burden on healthcare systems
and are associated with emotional, psychological and physical issues. Objective To provide …

To compare the cost of several common modalities used to treat non-genital warts in
immunocompetent patients, we identified studies published in English using standard …